> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Unveils ‘Plausible Mechanism’ Approval Pathway
- URL: https://www.fdaweb.com/fda-unveils-plausible-mechanism-approval-pathway/
- Published: 2025-11-12T12:00:00.000Z
- Updated: 2026-09-14T15:26:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5160209

FDA has introduced a new regulatory framework — the “plausible mechanism pathway” — designed to speed approval of highly personalized therapies for rare genetic diseases, according to an [11/12 article](https://www.nejm.org/doi/full/10.1056/NEJMsb2512695?ref=fdaweb.com) published in *The New England Journal of Medicine* by CBER director **Vinay Prasad** and commissioner **Marty Makary**. The accelerated pathway aims to provide a structured route to market for custom gene-editing and molecular therapies that target known disease-causing mutations, even when traditional randomized controlled trials are not feasible. The approach reflects the agency’s growing focus on bespoke treatments — medicines tailored to an individual patient’s unique genetic profile.

The article centers on the case study involving “Baby K.J.,” a newborn with carbamoyl-phosphate synthetase 1 (CPS1) deficiency, a rare metabolic disorder that leads to dangerously high ammonia levels. Within one week of an FDA-reviewed single-patient expanded access application, the child’s medical team delivered a base-editing therapy targeting the infant’s specific CPS1 mutation. Following treatment, the baby showed measurable clinical improvement and required fewer nitrogen-scavenging medications.

The FDA officials say the case exemplifies how the plausible mechanism pathway will function — prioritizing therapies that target a clearly defined molecular abnormality with strong biologic rationale, supported by known natural history data and observable clinical benefit.

Under the new framework, FDA says it will consider granting marketing authorization for individualized or small-batch therapies when several criteria are met:

- The disease mechanism is well understood and directly addressed by the therapy.
- The target is successfully drugged or edited, confirmed through appropriate clinical or laboratory evidence.
- There is a clear improvement in patient outcomes compared with the expected disease course.

Developers may begin with single-patient INDs, and once multiple cases show consistent success, FDA says it could grant marketing approval for a therapeutic platform capable of adapting to other similar mutations. Although the pathway is primarily intended for fatal or severely disabling rare pediatric diseases, it could eventually apply to common disorders with multiple genetic variants that share a common functional pathway.

The agency also notes its openness to non-animal models for preclinical evidence and allowing patients to serve as their own controls in certain studies, depending on the disease and feasibility of traditional trials.

Postmarketing requirements will include collecting real-world evidence to confirm ongoing efficacy and to monitor for off-target gene edits or safety concerns, the authors write. The article acknowledges potential criticism that existing FDA frameworks already accommodate such innovation, but argues that “current regulations are onerous and unnecessarily demanding” for one-off or rapidly evolving therapies.

Nearly three decades after sequencing the human genome, bespoke medicine is finally entering clinical reality — and the FDA intends to serve as “a partner and guide in ushering these therapies to market,” they conclude.